HMO direct costs and health care resources use after implementation of a monthly limit on sumatriptan

Area of Science:

• Health Economics
• Pharmacoeconomics
• Neurology

Background:

• Migraine treatment involves significant healthcare costs and resource utilization.
• Sumatriptan is a common acute treatment for migraine headaches.
• Health maintenance organizations (HMOs) implement cost-control measures, such as quantity limits, to manage prescription drug expenses.

Purpose of the Study:

• To compare healthcare costs and resource use in patients with migraine before and after a quantity limit on sumatriptan was introduced.
• To evaluate the impact of a sumatriptan reimbursement limit on an HMO's financial and patient care metrics.

Main Methods:

• A longitudinal, retrospective review of medical and pharmacy claims databases.
• Analysis of data from two six-month periods before and after a monthly limit (four tablets/injections) on sumatriptan reimbursement.
• Inclusion criteria: patients with migraine diagnosis codes or multiple prescription claims for migraine medications.

Main Results:

• Migraine-related medical costs and total medical costs showed non-significant increases (1.5% and 24.4%).
• Physician office visits for migraine increased by 7.8%; hospital admissions rose, but hospital costs decreased by 55.0%.
• Overall medication costs for migraine therapy decreased by 4.5% due to reduced sumatriptan use, despite increased use of other migraine drugs and prophylaxis medications.

Conclusions:

• Implementing a monthly limit on sumatriptan effectively decreased HMO pharmacy costs.
• The sumatriptan quantity limit did not significantly alter direct medical costs or healthcare resource utilization for migraine patients.
• Further research may be needed to assess long-term impacts and alternative cost-effective migraine management strategies.